These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37341786)

  • 21. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
    Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
    Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
    Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
    BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of maternal measles-rubella immunization on the 12-month-old infant's immune response to measles-mumps-rubella vaccine immunogenicity.
    Saffar MJ; Ajami A; Khalilian AR; Saffar H
    Eur J Clin Microbiol Infect Dis; 2009 Jul; 28(7):845-7. PubMed ID: 19229565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The active offering of measles, rubella and mumps vaccine in new mothers: the experience of health facilities in one of the Local Health Unit of Rome, Lazio, Italy].
    Santoro V; Pettinicchio V; Lancia A; Vazzoler C; De Luca F; Franco E
    Ig Sanita Pubbl; 2016; 72(6):589-597. PubMed ID: 28214912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders.
    Gentile I; Bravaccio C; Bonavolta R; Zappulo E; Scarica S; Riccio MP; Settimi A; Portella G; Pascotto A; Borgia G
    In Vivo; 2013; 27(3):377-82. PubMed ID: 23606694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mumps Antibody Titer in MMR-Vaccinated and Vaccine Naïve Children at a Public Hospital in Delhi.
    Saxena B; Ramachandran VG; Saha R; Shah D
    Indian Pediatr; 2021 Feb; 58(2):137-139. PubMed ID: 33632943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis.
    Sørup S; Englund H; Laake I; Nieminen H; Gehrt L; Feiring B; Trogstad L; Roth A; Benn CS
    Vaccine; 2022 Mar; 40(11):1583-1593. PubMed ID: 33518465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis.
    Schenk J; Abrams S; Theeten H; Van Damme P; Beutels P; Hens N
    Lancet Infect Dis; 2021 Feb; 21(2):286-295. PubMed ID: 32888410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
    Leuridan E; Maertens K; Wautier M; Hutse V; Theeten H
    Eur J Pediatr; 2015 Jul; 174(7):925-32. PubMed ID: 25579232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers.
    Hyle EP; Rao SR; Bangs AC; Gastañaduy P; Fiebelkorn AP; Hagmann SHF; Walker AT; Walensky RP; Ryan ET; LaRocque RC
    JAMA Pediatr; 2020 Feb; 174(2):e194515. PubMed ID: 31816033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.